Hormonal
A novel rice-based diabetes-specific formula (MFDM) containing physically modified rice flour, fructose, and isomaltulose significantly reduces postprandial glucose and insulin responses compared to a standard non-diabetes formula in adults with prediabetes or early type 2 diabetes, while eliciting similar hormonal (GLP-1, GIP, PYY, ghrelin) and satiety responses to a commercial diabetes-specific formula.
For individuals with prediabetes or early type 2 diabetes, consuming a meal replacement or formula containing physically modified rice flour, fructose, and isomaltulose (like the MFDM studied) can significantly blunt postprandial blood sugar and insulin spikes compared to standard non-diabetic formulas. This effect is comparable to established commercial diabetes-specific formulas, making it a viable, potentially more accessible option for managing post-meal glucose levels.
In Study 2, glucose and insulin responses were significantly lower after MFDM compared with SF (p-value<0.01 for both), however, those responses were similar between MFDM and DSF. MFDM suppressed hunger, promoted satiety, stimulated active GLP-1, GIP, and PYY, and suppressed active ghrelin although these changes were similar to SF and DSF.
Why this rating
Double-blinded, multi-arm randomized crossover trial in a specific clinical population (prediabetes/early T2D), though short-term (postprandial only).
Source
Effects of a novel rice-based diabetes-specific formula on postprandial glucose and gastrointestinal hormones: a double-blinded multi-arm randomized crossover trial
Supat Chaiyakul et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1141497
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →